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Lipid mobilization (lipolysis) in white adipose tissue
(WAT) critically controls lipid turnover and adiposity
in humans. While the acute regulation of lipolysis
has been studied in detail, the transcriptional deter-
minants of WAT lipolytic activity remain still largely
unexplored. Here we show that the genetic inactiva-
tion of transcriptional cofactor transducin beta-like-
related 1(TBLR1) blunts the lipolytic response of
white adipocytes through the impairment of cAMP-
dependent signal transduction. Indeed, mice lacking
TBLR1 in adipocytes are defective in fasting-induced
lipid mobilization and, when placed on a high-fat-
diet, show aggravated adiposity, glucose intoler-
ance, and insulin resistance. TBLR1 levels are found
to increase under lipolytic conditions in WAT of
both human patients and mice, correlating with
serum free fatty acids (FFAs). As a critical regulator
ofWAT cAMP signaling and lipidmobilization, proper
activity of TBLR1 in adipocytes might thus represent
a critical molecular checkpoint for the prevention
of metabolic dysfunction in subjects with obesity-
related disorders.
INTRODUCTION
White adipose tissue (WAT) has been described as an important
endocrine organ controlling systemic lipid metabolism (Galic
et al., 2010), and WAT lipid homeostasis is known to represent
a critical determinant of body weight, insulin sensitivity, and
peripheral energy handling in both mice and humans (Yu and
Ginsberg, 2005). Indeed, in humans, a combination of excessive
lipid storage and decreased removal leads to obesity and asso-
ciated comorbidities, including insulin resistance and type 2 dia-
betes (Langin, 2011), now affecting more than 500 million obese
people worldwide (Finucane et al., 2011). Excessive lipid loadCcauses adipocyte stress, which in turn accounts for many
adverse effects of obesity, particularly alterations in adipo-
cytokine release and a low-grade inflammatory response, ulti-
mately leading to the development of metabolic dysfunction
such as worsened insulin sensitivity and glucose intolerance
(Hotamisligil, 2006; Rasouli and Kern, 2008).
Due to their critical role in themaintenance of proper adipocyte
function, both storage and release of lipids inWAT are physiolog-
ically under tight hormonal control: whereas insulin promotes
triglyceride (TG) storage during the postprandial phase, cate-
cholamines trigger the breakdown of TG into glycerol and fatty
acids (‘‘lipolysis’’) to provide energy substrates for other organs,
including liver and skeletal muscle, during fasting (Yu and Gins-
berg, 2005).
Upon catecholamine binding to beta-adrenergic receptors,
the lipolytic cascade is induced by the activation of adenylate
cyclase to trigger cAMP/cAMP-dependent protein kinase A
(PKA) signal transduction, ultimately leading to the phosphoryla-
tion-dependent activation of critical downstream lipases, most
notably adipose TG lipase (ATGL) and hormone-sensitive lipase
(HSL), which catalyze the hydrolysis of triacylglycerol and
diacylglycerol, respectively (Zechner et al., 2012). Whereas
HSL is a direct PKA phosphorylation target, ATGL is indirectly
activated through the PKA-mediated phosphorylation of the lipid
droplet protein perilipin A and the subsequent release of the per-
ilipin-bound ATGL coactivator comparative gene identification
58 (CGI-58) (Lass et al., 2006).
Although lipolysis in WAT was recently found to critically
determine lipid turnover and adiposity in humans (Arner et al.,
2011), the molecular determinants of WAT lipolytic activity still
remain largely unknown. In this respect, transcriptional cofactor
complexes have been identified as important checkpoints in the
coordination of metabolic programs in various tissues, including
WAT (Herzig et al., 2001; Ostertag et al., 2010; Sommerfeld et al.,
2011). Indeed, we have recently identified a role for the trans-
ducin beta-like 1(TBL1)/TBL-related 1(TBLR1) transcriptional
cofactor complex in liver lipid metabolism (Kulozik et al., 2011),
originally identified as a component of the nuclear receptor
corepressor (NCoR)/silencing mediator for retinoid and thyroid
receptors (SMRT) complex (Guenther et al., 2000). TBL1 levelsell Metabolism 17, 575–585, April 2, 2013 ª2013 Elsevier Inc. 575
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Figure 1. TBLR1 Controls Adipocyte
Triglyceride Levels by Regulating Lipolysis
(A) TBL1, TBLR1 and valosin-containing protein
(VCP) protein levels in 3T3-L1 adipocytes 3 days
after infection with adenoviruses carrying shRNA
against TBL1, TBLR1, or a control sequence.
(B) TG levels in the same cells.
(C) Nonesterified fatty acid (NEFA) release from
3T3-L1 and primary adipocytes stimulated with
10 mM isoproterenol for 3 hr (± iso) measured in
supernatants of the cells.
(D) cAMP levels of 3T3-L1 adipocytes ± iso.
(E) Immunoblot of phosphorylated PKA targets
and HSL (at Serine 660) in 3T3-L1 adipocytes ± iso
compared to total HSL and actin levels.
(F) Ratio of S660 phosphorylated HSL to total HSL
as measured by quantitative analysis of immuno-
blots with ImageJ.
All values in bar graphs are expressed as means ±
SEM, n = 4, #p < 0.05 basal versus stimulated;
*p < 0.05, **p < 0.01, ***p < 0.001 control versus
TBLR1 shRNA-treated cells. See also Figure S1
and Table S1.
Cell Metabolism
TBLR1 Controls Lipolysisin the liver negatively correlate with hepatic TG content in
humans, and TBL1 levels are decreased in liver of mousemodels
of obesity and steatosis. Accordingly, acute knockdown of TBL1
in mouse livers promotes hepatic steatosis and hypertriglyceri-
demia, which is—at least in part—explained by reduced fatty
acid oxidation due to impaired TBL1 coactivator function for
nuclear receptor PPARa. The identification of TBL1/TBLR1 as
nuclear receptor-dependent regulators of liver lipid metabolism
provided the first indication that these cofactors might fulfill
broader functions in the control of energy homeostasis. How-
ever, the embryonic lethality of whole-body TBL1 or TBLR1
knockout mice (Perissi et al., 2010) thus far prevented the further
investigation of these cofactors in metabolic control.
RESULTS
TBLR1 but Not TBL1 Regulates Lipid Handling in
Adipocytes
The recently discovered role of the TBL1/TBLR1 transcriptional
complex in the manifestation of hepatic steatosis (Kulozik
et al., 2011) initially prompted us to explore potential additional
‘‘metaboloregulatory’’ functions of these cofactors. Given the
importance of adipose tissue for systemic energy handling, we
thus disrupted the activity of both cofactors by transducing
mature 3T3-L1 white adipocytes with adenoviruses expressing
TBL1- or TBLR1-specific or nonspecific control short hairpin
RNAs (shRNAs). TBL1 and TBLR1 shRNA treatment significantly
reduced the protein levels of both cofactors as compared
with control shRNA-treated cells (Figure 1A). Neither TBL1 nor
TBLR1 knockdown influenced adipogenesis in this system
(Figures S1I–S1K available online). Also, knockdown of TBLR1
had no effect on lipogenesis, fatty acid (FA) b-oxidation, glucose
uptake, and insulin signaling in the adipocytes (Figure S1A–S1D)
but led to a significant elevation of intracellular TG content
compared with controls (Figure 1B), indicative of reduced lipid576 Cell Metabolism 17, 575–585, April 2, 2013 ª2013 Elsevier Inc.removal from the cells. Indeed, loss of function of TBLR1 signif-
icantly blunted beta-adrenoceptor (isoproterenol)-stimulated
lipolysis in mature 3T3-L1 white adipocytes (Figures 1C and
S1E). The same was true for primary white adipocytes that had
been differentiated from the progenitor population within the
stromal-vascular fraction of inguinal white fat depots of wild-
type mice (Figures 1C and S1E). Importantly, overexpression of
TBLR1 in adipocytes caused a reduction in intracellular TG levels
and significantly augmented the lipolytic response (Figures S2A
and S2B).
Interestingly, deficiency in TBL1 had no effect on either TG
content or lipolysis under these conditions (Figures 1B, 1C,
and S1E), arguing for a specific regulatory importance of
TBLR1 but not TBL1 in white adipocyte lipid metabolism.
TBLR1 Controls Multiple Steps in the Lipolytic Cascade
As stated above, beta-adrenergic receptor activation and subse-
quent induction of cAMP signaling promotes lipolysis in white
adipocytes via the induction of protein kinase A (PKA)-mediated
phosphorylation of hormone-sensitive lipase (HSL) (Haemmerle
et al., 2002; Osuga et al., 2000) and the lipid droplet protein peril-
ipin, indirectly activating adipocyte triglyceride lipase (ATGL)
(Zechner et al., 2009). While inhibition of cellular phosphodies-
terase activity had no influence on the TBLR1-mediated inhibi-
tion of lipolysis (Figure S1F) and loss of TBLR1 did not alter the
PKA holoenzyme subunit composition (Figure S1G), intracellular
cAMP levels were found to be lower in mature 3T3-L1 white
adipocytes in response to TBLR1 deficiency (Figure 1D). Consis-
tent with these findings, activation of HSL by phosphorylation at
Ser660 and total PKA substrate phosphorylation, including peri-
lipin, upon beta-adrenergic stimulation was substantially blunted
in 3T3-L1 or primary adipocytes lacking TBLR1 (Figures 1E and
1F and data not shown). In turn, TBLR1 overexpression triggered
enhanced HSL as well as total PKA substrate phosphorylation
(Figure S2C).
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Figure 2. TBLR1 Regulates Lipolytic Gene Expression
(A and B) mRNA and protein expression of beta2- and beta3-adrenergic receptors (ADRB2 and ADRB3), HSL, and ATGL upon TBLR1 knockdown in 3T3-L1
adipocytes ± iso.
(C) HSL, ATGL, and PPRE promoter activity in 3T3-L1 preadipocytes transfected with TBLR1 or control shRNA and PPAR/RXR expression plasmids, treated with
or without 1 mM rosiglitazone for 24 hr. Luciferase activity normalized to b-galactosidase and the respective pGL3 empty vector control.
(D) NEFA release from 3T3-L1 adipocytes stimulated with 10 mM isoproterenol for 3 hr in the presence or absence of 1 mM rosiglitazone (rosi) for 24 hr.
(E) Immunoblot of ATGL, HSL, p-HSL, p-PKA target, and VCP levels in the same cells.
All values in bar graphs are expressed as means ± SEM, n = 4, #p < 0.05 basal versus stimulated; *p < 0.05, **p < 0.01, ***p < 0.001 control versus TBLR1 shRNA-
treated cells. See also Figure S2.
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TBLR1 Controls LipolysisTo further delineate the mechanism of TBLR1 action, we
performed global gene expression profiling in TBLR1-deficient
and wild-type control adipocytes. Consistent with the signifi-
cant impact of TBLR1 on adipocyte lipid metabolism, genetic
pathway analysis revealed that the pathway cluster containing
FA-associated, adipocytokine as well as peroxisome prolifera-
tor-activated receptor (PPAR) nuclear receptor pathways was
most strongly regulated by TBLR1 deficiency (Table S1 and Fig-
ure S1H). As TBLR1 affected lipolysis stimulated by differentCbeta2- and beta3-adrenoceptor-specific agonists as well as
by direct adenylate cyclase agonism (Figure S2D), we hypothe-
sized that TBLR1 controls multiple steps in the beta-adrenocep-
tor signaling cascade. Indeed, TBLR1 deficiency significantly
impaired the messenger RNA (mRNA) and protein expression
of the beta2- and beta3-adrenergic receptors (ADRB2 and
ADRB3) and of HSL and ATGL in this setting (Figures 2A, 2B,
and S2J). Consistent with these findings, the activities of HSL
and ATGL luciferase promoter constructs were significantlyell Metabolism 17, 575–585, April 2, 2013 ª2013 Elsevier Inc. 577
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TBLR1 Controls Lipolysisimpaired upon TBLR1-specific shRNA treatment (Figure 2C).
In keeping with a role of these genes in the PPARg nuclear
receptor pathway (Anghel et al., 2007; Rodriguez-Cuenca
et al., 2012a, 2012b), TBLR1 was found to physically interact
with the PPARg/RXRa complex and to regulate a PPAR
response element-dependent reporter gene in mature adipo-
cytes (Figures S2E, S2F, and 2C). Indeed, treatment of mature
adipocytes with a PPARg- but not PPARa- or PPARb/d-selective
agonist was able to partially rescue the defect in lipolysis and
inhibition of target gene expression mediated by TBLR1 defi-
ciency (Figures 2C–2E and S2G–S2I).
Adipocyte-Specific TBLR1 Deficiency Impairs
Fasting-Induced Lipid Mobilization
Thus far, our results supported the notion that the cell
autonomous transcriptional activity of TBLR1 controls multiple
beta-adrenoceptor and postreceptor checkpoints in white
adipocytes, thereby coordinating an integrated response of
cAMP-dependent free fatty acid (FFA) mobilization. To investi-
gate the functional impact of TBLR1 on WAT energy homeo-
stasis in vivo, we generated adipocyte-specific TBLR1 knockout
(ATKO)mice by introducing loxP sites flanking exon 5 of the Tblr1
gene and crossing homozygous animals with mice carrying Cre
recombinase under the control of the aP2 promoter (He et al.,
2003), thereby excising exon 5 and creating a stop codon in
exon 6 (Cre+/lox+/+; Figures S3A and S3B). At 8 weeks of age,
ATKO animals had no obvious alterations in body weight, body
fat content, and serum parameters (Figure S3C and data not
shown). Studies in humans have demonstrated that a chronic
lipolytic defect leads to overt adiposity over time (McQuaid
et al., 2011). In agreement, 14-week-old ATKO animals showed
increased body weight and body fat content, which was also
present at thermoneutral animal housing temperatures and
developed into a stable body weight difference at older ages
(8 months) as compared with their wild-type (WT) littermates
(Figure 3A and data not shown). No differences in food intake
and fecal energy content were observed in these animal cohorts
(Figures S3D and S3E). A 24 hr fasting challenge of 14-week-old
animals led to a substantial reduction of abdominal and inguinal
fat pad weights in WT mice (Figures 3B–3D), correlating with
WAT HSL and PKA substrate phosphorylation (Figure 3F). In
contrast, WAT TBLR1 deficiency impaired the fasting-induced
fat pad weight reduction, NEFA release, and HSL/PKA substrate
phosphorylation (Figures 3B–3F), indicating that TBLR1 is re-
quired for efficient lipid mobilization in vivo. Consistent with
this assumption, histological examination revealed a significantly
increased proportion of large adipocytes in WAT depots from
fasted ATKO mice as compared with WT littermates, whereas
adipocyte numbers remained unchanged (Figures 3G and S5I).
Isoproterenol-injected ATKO mice showed equally impaired
cAMP signaling (Figure 3H).
Furthermore, abdominal WAT and brown adipose tissue (BAT)
explants from ATKO mice showed a substantially impaired
release of NEFA and glycerol in response to beta-adrenoceptor
agonist treatment for 3 hr as compared with WT explants
(Figures 4A, 4B, S4A, and S4B). Consistent with the in vitro
data, loss of TBLR1 in AT depots abolished the isoproterenol-
mediated activation of HSL and PKA substrate phosphorylation
and led to a reduction in HSL and beta-adrenoceptor expression578 Cell Metabolism 17, 575–585, April 2, 2013 ª2013 Elsevier Inc.in ATKO mice (Figures 4C and S4C). Whereas BAT from ATKO
mice displayed mildly impaired uncoupling protein 1(UCP1)
expression, overall BAT histology and cold-induced increase in
oxygen consumption remained unchanged in these animals (Fig-
ure S3F, S3G, S5M, and S5N).
Lack of TBLR1 in Adipose Tissue Aggravates Obesity
and Metabolic Dysfunction
The importance of defective WAT FA handling for human
obesity (Arner et al., 2011; Karpe et al., 2011) next prompted
us to explore the contribution of fat-specific TBLR1 activity to
obesity-related metabolic dysfunction. To this end, we placed
WT and ATKOmice on either low-fat (LDF) or high-fat (HFD) diets
(10% or 60% calories from fat, respectively) for 8 weeks.
Whereas body weight mildly increased in ATKO animals under
LFD conditions as shown above, ATKO mice on a HFD gained
significantly more weight than their WT littermates (Figure 5A).
The difference in body weight gain was explained by increased
adiposity in the ATKO mice as determined by body composition
analysis and WAT depot sizes (Figures 5B and S5A–S5D). Also,
cell size distribution analysis revealed that ATKO mice had
substantially larger abdominal white adipocytes than did control
littermates on HFD (Figure 5C and S5F), correlating with reduced
lipolysis, HSL, and PKA substrate phosphorylation, and lower
expression of beta-adrenoceptors, HSL, and ATGL (Figures
5D, S5E, and S5G). In accordance with the increased adiposity
in ATKO mice, both glucose tolerance and systemic insulin
sensitivity were significantly impaired upon adipocyte TBLR1
deficiency (Figures 5G–5I and S5H), correlating with elevated
serum leptin and resistin levels, ectopic lipid accumulation
in muscle, WAT inflammatory marker gene expression, and
increased appearance of ‘‘crown-like’’ structures as compared
to controls, indicative of increased WAT damage (Figures 5E,
5F, and S5J–S5L). These data suggest that the lack of TBLR1
transcriptional activity in WAT abrogates adipocyte lipid mobili-
zation, thereby contributing to excess adiposity and metabolic
dysfunction upon exposure to fat-rich diet.
TBLR1 Expression Is Increased under Lipolytic
Conditions in Humans
To finally explore the relevance of our findings for the human situ-
ation, we analyzed TBLR1 mRNA expression in obese female
patients who underwent a controlled weight reduction program
(Rudofsky et al., 2011) (Table S2, part A). Consistent with mouse
data showing elevated TBLR1 mRNA levels during lipolytic con-
ditions like fasting, beta-adrenoceptor agonist treatment, and
lipopolysaccharide (LPS) injection (Figures S6A–S6C), TBLR1
mRNA expression in WAT was significantly increased in patients
after weight reduction as compared to the pre-weight-loss stage
(Figure 6A), substantiating the notion that lipid mobilization is
associated with elevation of TBLR1 expression in human and
mouse WAT. Indeed, TBLR1 but not TBL1 mRNA levels were
positively correlated with serum FFA and adiponectin levels
and negatively correlated with c-reactive protein (CRP) over
a wide body mass index (BMI) range (18.4 to 62.7 kg/m2) in
a female patient cohort (Figures 6B–6D and Table S2, part B).
Consistent with the correlation of WAT TBLR1 mRNA expres-
sion with beta2-adrenoceptor mRNA and FFA levels in mice (Fig-
ures S6D and S6E), TBLR1 mRNA expression also significantly
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Figure 3. Adipocyte-Specific TBLR1 Knockout Mice Display Increased Body Fat and Adipocyte Size due to Reduced Lipolysis
(A) ECHO-MRI body composition analysis of 14-week-old WT and adipocyte-specific TBLR1 knockout (ATKO) mice.
(B and C) Body fat content (B) and lean mass (C) of 14-week-old ATKO and WT mice before and after 24 hr fasting measured by ECHO-MRI.
(D) Abdominal and inguinal WAT depot weights and macroscopic appearance in the same mice.
(E) Lipolysis before and after 24 hr fasting calculated by total serum NEFA divided by total body fat mass before fasting (first panel), serum NEFA levels (second
panel), and relative induction by fasting (third panel).
(F) Immunoblot of p-HSL, p-PKA targets, HSL, ATGL, and VCP in abdominal WAT of the same animals.
(G) H&E-stained abdominal WAT slices and quantitation of adipocyte diameter in 8-week-old 48-hr-fasted mice.
(H) Immunoblot of p-HSL, p-PKA targets, HSL, ATGL, and VCP in abdominal WAT of male mice injected with 10 mg/kg isoproterenol for 30 min.
All values in bar graphs are expressed as means ± SEM, n = 6; #p < 0.05, ##p < 0.01 fed versus fasted, *p < 0.05, **p < 0.01WT versus ATKO. See also Figure S3.
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TBLR1 Controls Lipolysiscorrelated with both beta1 and beta2 adrenoceptor levels in
the same patients (Figures 6E and 6F), further supporting the
hypothesis that TBLR1 function in WAT is conserved and
coupled to adipose tissue lipid homeostasis and the lipolytic
pathway also in humans.
DISCUSSION
Proper metabolic flexibility to adapt to varying conditions of
energy availability is a crucial prerequisite for metabolic health.
Indeed, aberrant lipid turnover and particularly relative impair-
ment of WAT FFA release represent critical features of bothCmurine and human obesity, triggering WAT inflammation,
dysfunctional adipocytokine signaling, and eventually systemic
insulin resistance and glucose intolerance (Arner et al., 2011;
Samuel and Shulman, 2012).
In the current study, the transcriptional cofactor TBLR1 was
identified as a central player in adipocyte lipid metabolism. In
mice, adipose tissue TBLR1 deficiency had a substantial impact
on some of the most central pathways to adipocyte biology,
including fatty acid metabolism and adipocytokine expression
(Dahlman and Arner, 2010). In addition to reduced adrenoceptor
levels, TBLR1 knockdown particularly led to reduced ATGL and
HSL expression in adipocytes, thereby targeting the lipolyticell Metabolism 17, 575–585, April 2, 2013 ª2013 Elsevier Inc. 579
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Figure 4. Adipose Tissue Explants Isolated
from ATKO Mice Display Reduced Lipolysis
(A and B) NEFA and glycerol release from explants
isolated from abdominal WAT of WT or ATKO
mice upon isoproterenol stimulation (10 mM, 3 hr)
measured in supernatants.
(C) Immunoblot of HSL and PKA target phos-
phorylation and ATGL, HSL, and VCP protein
expression ± iso in abdominal WAT explants.
All values are expressed asmeans ± SEM, n = 6–8,
#p < 0.05 basal versus stimulated; *p < 0.05 WT
versus ATKO. See also Figure S4.
Cell Metabolism
TBLR1 Controls Lipolysiscascade at multiple critical nodes. Of note, this function of
TBLR1 seems to be largely conserved as WAT TBLR1 levels
correlated with serum FFA, adrenoceptor expression in WAT
and adiponectin levels also in a human patient cohort comprising
both lean and obese subjects.
It is tempting to speculate that parts of TBLR1 function inWAT
aremediated by a coactivating or derepressing effect on PPARg.
While PPARa or PPARb/d agonists failed to rescue the TBLR1
knockdownphenotype, thePPARg agonist rosiglitazone partially
restored lipolytic activity in TBLR1-deficient cells. Indeed,PPARg
has been shown to be a positive regulator of lipolytic gene
expression (Rodriguez-Cuenca et al., 2012a), and the TBLR1
target gene network—at least in part—overlapped with known
PPARg targets, including HSL, aquaporin 7, and inflammatory
markers (Anghel et al., 2007). This assumption is in congruence
with the direct physical interaction of TBLR1 with PPARg and
its obligate heterodimerization partner RXR. Alternatively, by
blocking the lipolytic response, TBLR1 deficiency could also
inhibit PPARg-mediated gene expression through an impaire-
ment in ligand availability, as activation of lipolysis by ATGL and
HSL has been shown to generate essential endogenous ligands
for PPAR activation (Haemmerle et al., 2011; Shen et al., 2011).
Whether and how this mechanism works in parallel with the dis-
cussed TBLR1 coactivator function for PPARg awaits further
detailed studies in the future. Intriguingly, PPARg activation by
adipocyte-specific knockout of the PPARg corepressor and
TBLR1 interaction partnerNCoRcreated anopposing phenotype
to adipose TBLR1 knockout, including decreased adipose tissue
inflammation and adipocyte size, increased adiponectin serum
levels, and improved glucose tolerance and insulin sensitivity
(Li et al., 2011). However, other nuclear-receptor/non-nuclear-
receptor-dependent mechanisms distinct from PPARg signaling
are also involved in TBLR1 adipocyte function, since, in contrast
to the phenotype of PPARg+/ mice (Rodriguez-Cuenca et al.,
2012a), we did not observe differences in adipocyte glucose
uptake or lipogenesis upon TBLR1 deficiency. Indeed, we noted
relative impairment of cAMP regulatory element binding protein
(CREB) phosphorylation in response to TBLR1 deficiency, which
might also mediate at least some aspects of TBLR1 function in
WAT lipid metabolism (Qi et al., 2009).
Impaired lipolytic capacity has been considered for a long time
to result in an improved overall metabolic status as reduced
liberation of FFA from adipose tissue stores is commonly thought
to protect peripheral tissues, including liver and skeletal muscle
from FFA-dependent lipotoxicity (Frayn et al., 1996; Samocha-
Bonet et al., 2012). Indeed, whole-body ATGL knockout mice580 Cell Metabolism 17, 575–585, April 2, 2013 ª2013 Elsevier Inc.display severely impaired lipolysis and subsequent accumula-
tion of TG in WAT and other tissues, leading to overall improved
insulin sensitivity and glucose tolerance (Haemmerle et al.,
2006). Also, adipocyte-specific ATGL deletion leads to blunted
lipolysis and severe fasting defects, but also slightly improves
systemic insulin sensitivity despite mild obesity (Wu et al.,
2012), and whole-body deficiency of monoglyceride lipase
(MGL), which catalyzes the final step in adipose tissue TG break-
down, was found to impair lipolysis and attenuate diet-induced
insulin resistance (Taschler et al., 2011).
While ATGL and MGL knockout mice parallel the TBLR1
deficient phenotype with respect to impaired lipolysis, lack
of adipose tissue TBLR1 action displayed overall impairment
in systemic metabolic function, supporting the notion that a
decreased release of FFA from adipocytes per se—and hence
elevated adipose tissue TG accumulation—does not necessarily
predict an improvement in systemic insulin sensitivity as already
highlighted by a number of studies in humans (Karpe et al., 2011).
In contrast to the dogmatic view on FFA-mediated lipotoxicity,
indeed, a series of recent studies showed that despite a more
than ten-fold difference in body fat content, FFA serum levels
only marginally differed between lean and obese human study
groups, indicating that serum FFA levels do not fully account
for metabolic complications as associated with the obese state
(McQuaid et al., 2011). Instead, systemic inflammation and
altered adipocytokine profile in obesity predispose for the
development of insulin resistance and glucose intolerance
(Hotamisligil, 2006; Rasouli and Kern, 2008).
The phenotype of the ATKOmice nowpoints toward the possi-
bility that indeed intrinsic deficiency in efficient FFA mobilization
in WAT may be sufficient to cause systemic metabolic dysfunc-
tion, maybe as a consequence of impaired WAT metabolic
flexibility upon an imbalanced equilibrium between lipid storage
and mobilization (Galgani et al., 2008), and/or the simultaneous
dysregulation of inflammatory and adipocytokine pathways as
observed upon TBLR1 deficiency. Indeed, the TBLR1 knockout
phenocopies the inhibition of lipolysis and of HSL and ATGL ex-
pression as generally observed in obese human patients (Jocken
et al., 2007; Langin et al., 2005; Large et al., 1999) and strongly
resembles the metabolic dysfunction in woman with polycystic
ovary syndrome (PCOS), including adipocyte hypertrophy,
attenuated lipolytic response to catecholamine exposure,
obesity, adipose tissue inflammation, and insulin resistance (Villa
and Pratley, 2011).
In line with the recently discovered function of the TBL1/
TBLR1 cofactor complex in hepatic fatty acid oxidation and
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Figure 5. ATKO Mice on a High-Fat Diet Display Aggravated Adiposity and Insulin Resistance
(A) Body weight of wt or ATKO mice fed a low-fat (LFD) or high-fat (HFD) diet for 8 weeks starting from 6 weeks of age onward.
(B) ECHO-MRI body composition analysis after 8 weeks of LFD/HFD feeding.
(C) H&E-stained abdominal WAT slices.
(D) Immunoblot of p-HSL, p-PKA targets, HSL, ATGL, and RNA polymerase II in abdominal WAT.
(E and F) Serum leptin and resistin levels.
(G) Homeostatic model assessment index (HOMA-IR) of WT or ATKO mice fed a LFD/HFD for 6 weeks.
(H and I) Serum glucose and insulin levels in the same mice during an intraperitoneal glucose tolerance test and total area under the curve (AUC).
All values in bar graphs are expressed asmeans ± SEM, n = 8, #p < 0.05 LFD versus HFD; *p < 0.05, **p < 0.01WT versus ATKO. In (A), (H), and (I), * and $ indicate
significance (p < 0.05) within the LFD and HFD groups, respectively. See also Figure S5.
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TBLR1 Controls Lipolysisthe induction of hepatic steatosis upon liver-specific TBL1/
TBLR1 deficiency (Kulozik et al., 2011), our current findings
overall position the TBLR1 transcriptional cofactor as an
important component of the metabolic flexibility program inCWAT and critical node in systemic energy homeostasis. The
correlation of TBLR1 levels with metabolic parameters in human
subjects indicates that tissue-specific targeting of TBLR1
may represent a conserved, yet unappreciated, approach toell Metabolism 17, 575–585, April 2, 2013 ª2013 Elsevier Inc. 581
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Figure 6. TBLR1 Gene Expression Is Differ-
entially Regulated in Human WAT upon
Weight Loss and Correlates with Obesity
Markers and Adrenoceptor Expression
(A) TBLR1 mRNA expression in visceral WAT of
female patients who underwent a weight loss
program for 52 weeks (n = 12).
(B–F) Pearson correlation coefficients and p values
shown for normalized WAT TBLR1 mRNA levels
versus serum adiponectin levels (B), serum FFA
levels (C), serum CRP levels (D), and WAT beta1-
and beta2-adrenergic receptor mRNA levels
(E and F) in a patient cohort representing BMIs
ranging from 18.4 to 62.7 kg/m2.
**p < 0.01. See also Figure S6 and Table S2.
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TBLR1 Controls Lipolysiscounteract metabolic inflexibility in energetic stress conditions,
including obesity.
EXPERIMENTAL PROCEDURES
Recombinant Adenoviruses
Adenoviruses expressing TBL1- or TBLR1-specific or nonspecific shRNA
under the control of the U6 promoter or the TBLR1 complementary DNA
(cDNA) sequence under control of the CMV promoter were cloned as
described previously (Herzig et al., 2003) (Herzig et al., 2001). Viruses were
purified by the cesium chloride gradient and dialyzed against PBS buffer
containing 10% glycerol. shRNA sequences were as follows: TBL1, 50-
GCGAGGATATGGAACCTTAAT-30; TBLR1, 50-GGATGTCACGTCTCTAGA
TTG-30; nonspecific shRNA, 50-GATCTGATCGACACTGTAATG-30.
Animals
Eight-week-old C57Bl6/N, NMRI, and db/db mice were obtained from Charles
River Laboratories (CRL, Brussels, Belgium). Floxed TBLR1mice were created
by TaconicArtemis (Cologne, Germany) and bred with B6.Cg-Tg(Fabp4-cre)
1Rev/J mice (He et al., 2003) obtained from CRL. Data obtained from female
mice are shown unless stated otherwise. For starvation experiments, mice
were fasted or refed for the indicated times with free access to water. For
CL316,243 (CL) treatment, NMRI mice were injected intraperitoneally (i.p.)
with 1 mg/kg CL316243 (Tocris Bioscience, Bristol) in 0.9% NaCl and sacri-
ficed 3 or 8 hr later. Isoproterenol in PBS was injected i.p. into 6-month-old
male mice at 10 mg/kg lean mass, and mice were sacrificed 30 min after injec-
tion. Sepsis in C57Bl6 mice was induced in 18-hr-starved animals by i.p. injec-
tion of 20 mg LPS/kg (Sigma, Munich) for 8 hr. PBS controls were starved after
the injection until sacrifice to mimic the anorexia accompanying sepsis.
Glucose tolerance test was performed in 6-hr-fasted animals by i.p. injection
of 2 g/kg glucose. When stated HFD/LFD, mice were fed a HFD (Research
Diets, New Brunswick; 60% calories from fat) or a LFD (10% calories from
fat) starting at the age of 6 weeks unless stated otherwise. Indirect calo-
rimetry was performed in PhenoMaster cages (TSE Systems, Bad Homburg,
Germany) with individually housed mice at 30C, 22C, and 4C, respectively.582 Cell Metabolism 17, 575–585, April 2, 2013 ª2013 Elsevier Inc.Calculations of resting metabolic rate (RMR)
and body-weight-adjusted oxygen consumption
were performed as described (Tscho¨p et al.,
2012). All mice were maintained on a 12 hr light-
dark cycle at 24C with regular unrestricted diet
unless stated otherwise. Organs, including liver,
fat pads, and gastrocnemius muscles, were
collected, snap frozen, pulverized, and used for
further analysis. Total body fat content was deter-
mined by an Echo magnetic resonance imaging
(ECHO-MRI) body composition analyzer (Echo
Medical Systems, Houston, TX). Fecal energy
content was measured with the IKA C7000 calo-
rimeter (IKA, Staufen, Germany). Animal handlingand experimentation was done in accordance with National Institutes of Health
guidelines and approved by local authorities.
Histological Examinations
Tissues were fixated in 4% paraformaldehyde for 24 hr, and paraffin-
embedded tissues were sliced and stained with hematoxylin and eosin
(H&E) staining by standard procedures. Cell sizes were quantified in two layers
of the tissue and a minimum of 100 cells/layer by Wimasis (Munich, Germany).
For adipose tissue whole mount immunofluorescence, 4 mm visceral fat pad
pieces were dissected and fixated in 4% paraformaldehyde for 1 hr, then
blocked in 1% BSA before incubation with perilipin and F4/80 antibodies
(2 mg/ml) over night at 4C. After three washes, samples were incubated
with fluorescence-conjugated secondary antibodies and imaged in a fluores-
cence microscope (Zeiss, Jena, Germany).
Blood Metabolites
Serum levels of glucose, insulin, glycerol, NEFAs, leptin, and resistin were
determined with an automatic glucose monitor (One Touch, Lifescan, Neckar-
gemu¨nd, Germany) or commercial kits (Mercodia, Uppsala, Sweden; Sigma,
Munich, Germany; Wako, Neuss, Germany; Merck Millipore, Schwalbach,
Germany). Total NEFA levelswere calculatedwith the assumption that amouse
has 1 ml serum.
Tissue Explants
Abdominal, inguinal and interscapular fat pads were isolated from mice and
sliced into equally sized pieces of 50 mg. Explants were washed twice in
Krebs-Ringer (KR) buffer (115 mM NaCl, 5.9 mM KCl, 1.2 mM MgCl2,
1.2 mM NaH2PO4, 1.2 mM Na2SO4, 2.5 mM CaCl2, and 25 mM NaHCO3)
and stimulated with 10 mM isoproterenol (Calbiochem, Merck, Darmstadt)
for 3 hr in KR buffer supplemented with 5% BSA, 5 mM glucose, and 25 mM
HEPES/KOH (pH 7.5). NEFA and glycerol were measured from the superna-
tants and was calculated relative to protein content.
Cell Culture
3T3-L1 preadipocytes were cultured in low (1 g/l)-glucose Dulbecco’s
modified Eagle’s medium containing 10% fetal calf serum (FCS) and
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TBLR1 Controls Lipolysis1% penicillin/streptomycin (P/S) and differentiated into mature white adipo-
cytes 2 days after confluency by the addition of 1 mg/ml insulin, 0.5 mM 3-iso-
butyl-1-methylxanthine (IBMX), 0.25 mM dexamethasone, and 1/1000 volume
ABP (50 mg/ml L-ascorbate, 1 mM biotin, 17 mM pantothenate) in high
(4.5 g/l)-glucose DMEM containing 10% FCS and 1% P/S. Primary stromal-
vascular fractions (SVFs) were isolated from mouse inguinal fat depots,
cultured, and differentiated into mature primary adipocytes as described
(Rodeheffer et al., 2008). Cells were transduced with recombinant adenovi-
ruses at a multiplicity of infection (MOI) of 1,000 (primary adipocytes) or 500
(3T3-L1 adipocytes) with 0.5 mg/ml poly-L-lysine. For analysis of adipocyte
differentiation upon TBL/R1 knockdown, confluent 3T3-L1 preadipocytes
were transduced with adenoviruses carrying respective shRNAs at an MOI
of 500 2 days prior to induction of differentiation. Triglyceride accumulation
was measured by oil red O staining. In brief, cells were fixated in 10% formal-
dehyde in PBS for 1 hr, washed in 60% isopropanol, and dried. Triglycerides
were stained with six parts oil red O solution (0.7 g oil red O in 200 ml isopro-
panol) and 4 parts H2O. For luciferase assays, 3T3-L1 preadipocytes were
transfected with plasmids encoding TBLR1 shRNA or overexpression con-
structs, PPRE, HSL, and ATGL promoter sequences, PPAR and RXR expres-
sion constructs, and b-galactosidase cDNA with Lipofectamine (Invitrogen).
Mature adipocytes were transfected with a NEON transfection device
(Invitrogen). Primer sequences were as follows: pATGLfor, 50- GACGGC
TAGCTAGGACCCCGGCTCTCTTTTCAG-30; pATGLrev, 50- GCGAAAGCTTC
GGCGGAGGCGGAGACGCTGTGC-30; pHSLfor, 50- CCCCACGCGTGTCAT
TATGATCAGCCCA-30; pHSLrev, 50- TTTTAGATCTCAAGCTGGCACAGCA
GGTCTG-30. Lipolysis assays were performed in mature adipocytes 9 to
12 days after induction of differentiation. After preincubation in KR buffer for
2 hr, cells were stimulated with 10 mM isoproterenol (iso), 10 mM norepineph-
rine (NE), 100 nM procaterol (pro), 10 mM CL, 10 mM forskolin (fsk), or 0.5 mM
IBMX for 3 hr in KR buffer supplemented with 5% BSA, 5 mM glucose, and
25 mM HEPES/KOH (pH 7.5). cAMP assays were performed with standard
kits (Cayman Chemicals, Ann Arbor). Glucose uptake and lipogenesis were
stimulated by 10 nM insulin in KR buffer supplemented with 3% BSA,
25 mM HEPES/KOH (pH 7.5) and 1 mM glucose spiked with 0.1 mCi
D-[14C(U)]-Glucose (Perkin Elmer, Waltham). Cells were lysed with 0.5 M
NaOH, and defined amounts were used to measure overall glucose uptake
or to isolate TG andmeasure lipogenesis by counting of 14C lipid incorporation.
Glucose uptake and lipogenesis were calculated as the percent induction
by insulin. Palmitate oxidation was measured from adipocytes treated with
200 mM palmitate spiked with 0.5 mCi/ml 3H palmitate in KR buffer
supplemented with 3% BSA, 5 mM glucose, and 25 mM HEPES/KOH
(pH 7.5) for 3 hr. The aqueous phase of the supernatants was isolated by
addition of 2:1 chloroform:methanol, and disintegrations per minute were
counted in a scintillation counter. For protein and TG measurements, cells
were lysed as described (Haas et al., 2009). NEFAs, TG, and glycerol were
measured from cell lysates or supernatants with commercial kits (Wako,
Neuss; Sigma, Munich). Proteins were quantified by the BCA method (Fisher
Scientific, Schwerte). TG, NEFAs, and glycerol were normalized to protein
levels.
Protein Analysis
Proteins were extracted from frozen organ samples or cultured adipocytes as
described (Rose et al., 2011), and extracts were separated on 8% SDS-poly-
acrylamide gels and blotted onto nitrocellulose membranes. Western blot
assays were performed with antibodies specific for Actin, Pol II, RXR,
ADRB2, ADRB3 (Santa Cruz, Heidelberg), TBLR1 (Novus Biologicals, Little-
ton), Perilipin A, TBL1, VCP, PPARg (Abcam, Cambridge), GFP (Invitrogen,
Karlsruhe), AKT, p-AKT Ser473, p-HSL Ser660, ATGL, p-PKA substrate (Cell
Signaling, Danvers), or HSL (Chemicon, Hofheim). The ratio of p-HSL/HSL
was calculated with ImageJ. For immunoprecipitation, differentiated 3T3-L1
adipocytes on 10 cm plates were lysed in 1 ml lysis buffer (20 mM HEPES/
KOH [pH 7.4], 125 mM NaCl, 0.5 mM EDTA, 0.1% Igepal, and 10% Glycerol)
containing protease inhibitor for 30 min on ice. After spinning (13,000 rpm,
4C, 30 min), supernatants were collected and incubated with protein A/G
agarose beads and 4 mg of the respective antibody over night at 4C on
a rotating wheel. Protein-bound beads were washed three times with lysis
buffer, and proteins were eluted by the addition of SDS sample buffer and
subjected to immunoblotting.CQuantitative Taqman RT-PCR
Total RNA was extracted from frozen organ samples or cultured adipocytes
with QIAzol and the RNeasy (QIAGEN, Hilden) kit. RNA was extracted from
human adipose tissue by Trizol. cDNA was prepared by reverse transcription
with M-MuLV enzyme and Oligo dT primer (Fermentas, St. Leon-Rot). cDNAs
were amplified with assay-on-demand kits and an ABI StepOnePlus sequence
detector (Applied Biosystems, Darmstadt). TBLR1 exon 5 was detected
by SYBR PCR using the following primers: TBLREx5for, 50-TGCTGCC
GCCACTAACCAGC-30; TBLREx5rev, 50-TGTGCTCCATTCTCCTCCCC-30.
RNA expression data were quantified according to the delta Ct method as
described (Livak and Schmittgen, 2001) and normalized to levels of TATA-
box binding protein RNA for mouse or ubiquitin C (UBC) for human adipose
tissue.
Microarray Analysis
Gene expression profiling was performed in 3T3-L1 adipocytes transduced
with TBLR1 or control shRNA carrying adenoviruses. RNA isolation, cRNA
synthesis, and hybridization to Mouse Genome 430 2.0 arrays (Affymetrix,
Freiburg) were performed according to the manufacturer’s recommendations.
Three arrays per group were hybridized. CustomCDF by Brainarray with Entrez
based gene definitions (Entrez basic version 13) was used to annotate the
arrays (Sandberg and Larsson, 2007). The Raw fluorescence intensity values
were normalized by application of quantile normalization. Differential gene
expression was analyzed based on ANOVA with a commercial software
package (SAS JMP8 Genomics, version 4, SAS Institute, Cary, NC). A false
positive rate of 0.05 with FDR correction was taken as the level of significance.
Pathways belonging to various cell functions were obtained from public
external databases (KEGG, http://www.genome.jp/kegg/). A Fisher’s exact
test was performed to detect the significantly regulated pathways.
Human Subjects
For the fasting study, 12 obese subjects underwent a weight reduction
program (OPTIFAST 529) for 52 weeks (BMI = 45.6 ± 2.5 kg/m2 before,
39.0 ± 2.2 kg/m2 after) and WAT TBLR1 mRNA expression was measured
before and after the weight reduction; mRNA levels were normalized to
36B4. This study has been approved by the ethics committee at Heidelberg
University, and all patients gave written informed consent. For the second
study, TBLR1 mRNA expression in omental WAT of 31 female patients (BMI
ranging from 18.4 to 62.7 kg/m2) was normalized to UBC mRNA levels and
correlated to serum parameters or WAT adrenoceptor expression with Pear-
son correlation. This study has been approved by the ethics committee of
the Medical University of Vienna and the General Hospital Vienna, and all
patients gave written informed consent.
Statistical Analysis
Statistical analyses were performed with a two-way ANOVA with Bonferroni-
adjusted posttests or Student’s t test in one-factorial designs, respectively.
p < 0.05 was considered statistically significant. Error bars in figures represent
the SEM.
ACCESSION NUMBERS
Microarray data sets have been deposited in the NCBI Gene Expression
Omnibus (GEO) database under accession number GSE43658.
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